BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND FAS, FAS1, 355, ENSG00000026103, FASTM, APO-1, P25445, CD95, ALPS1A, TNFRSF6, APT1 AND Treatment
226 results:

  • 1. TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mTOR signaling axis by binding to MYH9.
    Hu R; Cao Y; Wang Y; Zhao T; Yang K; Fan M; Guan M; Hou Y; Ying J; Ma X; Deng N; Sun X; Zhang Y; Zhang X
    Breast Cancer Res; 2024 Mar; 26(1):48. PubMed ID: 38504374
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Efficacy of adding levofloxacin to gemcitabine and nanoparticle-albumin-binding paclitaxel combination therapy in patients with advanced pancreatic cancer: study protocol for a multicenter, randomized phase 2 trial (T-CORE2201).
    Imai H; Sakamoto Y; Takahashi S; Shibata H; Sato A; Otsuka K; Amagai K; Takahashi M; Yamaguchi T; Ishioka C
    BMC Cancer; 2024 Feb; 24(1):262. PubMed ID: 38402399
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial.
    Zhang D; Benedikt Westphalen C; Quante M; Waldschmidt DT; Held S; Kütting F; Dorman K; Heinrich K; Weiss L; Boukovala M; Haas M; Boeck S; Heinemann V; Probst V
    Eur J Cancer; 2024 Apr; 201():113926. PubMed ID: 38401449
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Primary retroperitoneal lymph node dissection for clinical stage II seminoma: A systematic review and meta-analysis of safety and oncological effectiveness.
    Kardoust Parizi M; Margulis V; Bagrodia A; Bekku K; Klemm J; Matsukawa A; Alimohammadi A; Motlagh RS; Mostafaei H; Laukhtina E; Shariat SF
    Urol Oncol; 2024 Apr; 42(4):102-109. PubMed ID: 38360519
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Targeting endogenous fatty acid synthesis stimulates the migration of ovarian cancer cells to adipocytes and promotes the transport of fatty acids from adipocytes to cancer cells.
    Grunt TW; Wagner R; Ries A; Berghoff AS; Preusser M; Grusch M; Valent P
    Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38214315
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Chimeric Antigen Receptor T Cell Therapy for Pancreatic cancer: A Review of Current Evidence.
    Czaplicka A; Lachota M; Pączek L; Zagożdżon R; Kaleta B
    Cells; 2024 Jan; 13(1):. PubMed ID: 38201305
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Ovarian cancer treatment and natural killer cell-based immunotherapy.
    Fan Z; Han D; Fan X; Zhao L
    Front Immunol; 2023; 14():1308143. PubMed ID: 38187402
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Mesenchymal Stem Cell Microvesicles from Adipose Tissue: Unraveling Their Impact on Primary Ovarian cancer Cells and Their Therapeutic Opportunities.
    Szyposzynska A; Bielawska-Pohl A; Murawski M; Sozanski R; Chodaczek G; Klimczak A
    Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958844
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Strong apoptotic response of testis tumor cells following cisplatin treatment.
    Köberle B; Usanova S; Piee-Staffa A; Heinicke U; Clauss P; Brozovic A; Kaina B
    Int Urol Nephrol; 2024 Mar; 56(3):1007-1017. PubMed ID: 37891379
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models.
    Wang T; Zhang K; You F; Ma R; Yang N; Tian S; An G; Yang L
    Life Sci; 2023 Oct; 331():122024. PubMed ID: 37574043
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Dynamic contrast-enhanced MRI to characterize angiogenesis in primary epithelial ovarian cancer: An exploratory study.
    Lindgren A; Anttila M; Arponen O; Hämäläinen K; Könönen M; Vanninen R; Sallinen H
    Eur J Radiol; 2023 Aug; 165():110925. PubMed ID: 37320880
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Association of treatment Strategies and Tumor Characteristics With Overall Survival Among Patients With Anaplastic Thyroid cancer: A Single-Institution 21-Year Experience.
    Wu SS; Lamarre ED; Yalamanchali A; Brauer PR; Hong H; Reddy CA; Yilmaz E; Woody N; Ku JA; Prendes B; Burkey B; Nasr C; Skugor M; Heiden K; Chute DJ; Knauf JA; Campbell SR; Koyfman SA; Geiger JL; Scharpf J
    JAMA Otolaryngol Head Neck Surg; 2023 Apr; 149(4):300-309. PubMed ID: 36757708
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Extrinsic apoptosis and senescence involved in growth kinetics of seminoma to cisplatin.
    Yin Y; Peng J; Zheng X; Zhou J; Wang Y; Dai Y; Yin G; Tang Y
    Clin Exp Pharmacol Physiol; 2023 Feb; 50(2):140-148. PubMed ID: 36222180
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Superior Anticancer Potential of Nano-Paclitaxel Combined Bevacizumab treatment in Ovarian cancer.
    Qu N; Wang C; Meng Y; Gao Y
    Curr Pharm Biotechnol; 2023; 24(9):1204-1212. PubMed ID: 36221878
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. The co-occurrence of both breast- and differentiated thyroid cancer: incidence, association and clinical implications for daily practice.
    Piek MW; de Boer JP; van Duijnhoven F; van der Wal JE; Vriens M; van Leeuwaarde RS; van der Ploeg IMC
    BMC Cancer; 2022 Sep; 22(1):1018. PubMed ID: 36163009
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Multikinase Inhibitors for the treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid cancer: Global Noninterventional Study (RIFTOS MKI).
    Brose MS; Smit JWA; Lin CC; Tori M; Bowles DW; Worden F; Shen DH; Huang SM; Tsai HJ; Alevizaki M; Peeters RP; Takahashi S; Rumyantsev P; Guan R; Babajanyan S; Ozgurdal K; Sugitani I; Pitoia F; Lamartina L
    Thyroid; 2022 Sep; 32(9):1059-1068. PubMed ID: 35950621
    [No Abstract]    [Full Text] [Related]  

  • 17. Identification of key genes and pathways related to cancer-associated fibroblasts in chemoresistance of ovarian cancer cells based on GEO and TCGA databases.
    Han L; Guo X; Du R; Guo K; Qi P; Bian H
    J Ovarian Res; 2022 Jun; 15(1):75. PubMed ID: 35739532
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy.
    Baleeiro RB; Bouwens CJ; Liu P; Di Gioia C; Dunmall LSC; Nagano A; Gangeswaran R; Chelala C; Kocher HM; Lemoine NR; Wang Y
    Oncoimmunology; 2022; 11(1):2080329. PubMed ID: 35655709
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Resistant prolactinomas: a case series of 26 patients.
    Eshkoli T; Fraenkel M; Zaid D; Cohen D; Yoel U; Tsvetov G; Gorshtein A; Goldbart A; Greenman Y; Shimon I
    Endocrine; 2022 Aug; 77(2):349-356. PubMed ID: 35604631
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. NOD1 activation promotes cell apoptosis in papillary thyroid cancer.
    Bai N; Liu C; Zhang X; Cheng Y; Hou D
    Pathol Res Pract; 2022 May; 233():153880. PubMed ID: 35430507
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 12.